CO5660259A2 - Cristal derivado de benzimidazol y procedimiento para producirlo - Google Patents

Cristal derivado de benzimidazol y procedimiento para producirlo

Info

Publication number
CO5660259A2
CO5660259A2 CO05115024A CO05115024A CO5660259A2 CO 5660259 A2 CO5660259 A2 CO 5660259A2 CO 05115024 A CO05115024 A CO 05115024A CO 05115024 A CO05115024 A CO 05115024A CO 5660259 A2 CO5660259 A2 CO 5660259A2
Authority
CO
Colombia
Prior art keywords
benzimidazol
procedure
produce
crystal
crystal derived
Prior art date
Application number
CO05115024A
Other languages
English (en)
Inventor
Mitsuri Teramoto
Naoki Tsuchiya
Hiroshi Saitoh
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5660259(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CO5660259A2 publication Critical patent/CO5660259A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un cristal de ácido 4-(1-((4-metilbenzotiofen-3-il)metil)benzimidazol-2-iltio)butanoico o un solvato del mismo.Un procedimiento para producir un cristal B, que comprende llevar a cabo una cristalización por enfriamiento a partir de una solución de ácido 4-(1-((4-metilbenzotiofen-3-il)metil)benzimidazol-2-iltio)butanoico, y ácido acético, tetrahidrofurano, metanol, 2-butona, agua, o un solvente mixto de dos o más clases seleccionadas entre estos.
CO05115024A 2003-05-14 2005-11-11 Cristal derivado de benzimidazol y procedimiento para producirlo CO5660259A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14

Publications (1)

Publication Number Publication Date
CO5660259A2 true CO5660259A2 (es) 2006-07-31

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05115024A CO5660259A2 (es) 2003-05-14 2005-11-11 Cristal derivado de benzimidazol y procedimiento para producirlo

Country Status (25)

Country Link
US (1) US7649008B2 (es)
EP (1) EP1626048A4 (es)
JP (1) JPWO2004101551A1 (es)
KR (1) KR20060011997A (es)
CN (1) CN1788007A (es)
AR (1) AR044340A1 (es)
AU (1) AU2004238708A1 (es)
BR (1) BRPI0410266A (es)
CA (1) CA2523978A1 (es)
CL (1) CL2004001034A1 (es)
CO (1) CO5660259A2 (es)
EC (1) ECSP056162A (es)
IS (1) IS8177A (es)
MA (1) MA27805A1 (es)
MX (1) MXPA05011851A (es)
NO (1) NO20055181L (es)
NZ (1) NZ542978A (es)
PE (1) PE20050203A1 (es)
RU (1) RU2332417C2 (es)
SA (1) SA04250117B1 (es)
TN (1) TNSN05288A1 (es)
TW (1) TW200505911A (es)
UA (1) UA81493C2 (es)
WO (1) WO2004101551A1 (es)
ZA (1) ZA200508640B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
WO2005018672A1 (ja) * 2003-08-22 2005-03-03 Teijin Pharma Limited キマーゼ阻害剤を有効成分として含有する薬剤
WO2006052026A1 (ja) * 2004-11-12 2006-05-18 Teijin Pharma Limited ベンズイミダゾール誘導体の酸性塩及びその結晶
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72244T1 (de) 1986-03-21 1992-02-15 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
JP3668494B2 (ja) 1994-05-31 2005-07-06 帝人株式会社 ナフタレン誘導体
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
CA2336909C (en) 1998-07-15 2009-10-20 Teijin Limited Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
IL150565A0 (en) 2000-01-17 2003-02-12 Teijin Ltd Benzimidazole derivatives and pharmaceutical compositions containing the same
JP3999128B2 (ja) 2001-02-22 2007-10-31 帝人株式会社 ベンゾ［ｂ］チオフェン誘導体、およびその製造方法
US6774245B2 (en) 2001-05-07 2004-08-10 Teijin Limited 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation
CA2442761A1 (en) 2001-08-24 2003-03-06 Teijin Limited Drugs comprising chymase inhibitors and ace inhibitors as effective ingredients
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
NZ542978A (en) 2009-04-30
IS8177A (is) 2005-12-13
EP1626048A4 (en) 2008-11-12
ECSP056162A (es) 2006-04-19
US20060293375A1 (en) 2006-12-28
NO20055181L (no) 2006-01-24
TW200505911A (en) 2005-02-16
AR044340A1 (es) 2005-09-07
PE20050203A1 (es) 2005-03-26
NO20055181D0 (no) 2005-11-03
RU2332417C2 (ru) 2008-08-27
SA04250117B1 (ar) 2009-09-02
JPWO2004101551A1 (ja) 2006-07-13
CA2523978A1 (en) 2004-11-25
MXPA05011851A (es) 2006-02-17
US7649008B2 (en) 2010-01-19
EP1626048A1 (en) 2006-02-15
ZA200508640B (en) 2007-02-28
WO2004101551A1 (ja) 2004-11-25
TNSN05288A1 (en) 2007-07-10
AU2004238708A1 (en) 2004-11-25
KR20060011997A (ko) 2006-02-06
RU2005138868A (ru) 2006-07-10
CL2004001034A1 (es) 2005-03-28
MA27805A1 (fr) 2006-03-01
BRPI0410266A (pt) 2006-05-16
CN1788007A (zh) 2006-06-14
UA81493C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ES2545102T3 (es) Procedimiento para producir compuestos de lactamida, nuevos compuestos de lactamida y formulaciones que contienen compuestos de lactamida
ECSP056071A (es) Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso
EA200601584A1 (ru) Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
BR0316916A (pt) Processo de preparação de formas cristalinas dos enantiÈmeros óticos, formas polimórficas de enantiÈmeros levógiros ou dextrógiros de modafinil, solvatos de dimetilcarbonato e de acetonitrila de enantiÈmeros levógiros ou dextrógiros de modafinil, processo de conversão, processo de preparação de modafinil oticamente ativo, processo de preparação de um dos enantiÈmeros de modafinil, composições farmacêuticas, usos das formas polimórficas do (-)-modafinil ou do (+)-modafinil
GT199900216A (es) Polimorfos de acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazol carboxilico y metodo de produccion de los mismos.
CL2010000284A1 (es) Procedimientos para la preparacion de 4-(2-cianoetenil)-2,6-dimetilanilina a partir de 2,6-dimetil-4-sustituida-anilina. (divisional de solicitud 2003-01598)
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
BRPI0608958B8 (pt) método para transmissão de dados em um sistema de comunicação e método para transmissão de dados por uma estação de base em um sistema de comunicação
BR0005488A (pt) Processo para a preparação de carbonato de vinileno, e o uso do mesmo
CO5660259A2 (es) Cristal derivado de benzimidazol y procedimiento para producirlo
CR9507A (es) Sulfonamidas de diarisulfona y sus usos
CU20080213A7 (es) Nuevo procedimiento para la preparación de un intermediario útil en la preparación de imidazotriazinonas sustituidas con sulfonamida
NI200900035A (es) Procedimiento de preparación de halogenuros de n-alquil-naltrexona.
PE20060988A1 (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
DE602006010584D1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
EA200500898A1 (ru) Способ получения оптически чистых активных соединений
BR0309575A (pt) Processo para a preparação de uma solução aquosa de acrilato de metal alcalino, e, uso de uma solução aquosa de acrilato de metal alcalino
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
PE20091369A1 (es) Metodo para la preparacion de acido montelukast en un medio liquido ionico
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
AR041639A1 (es) Metodo para la sintesis de un compuesto de bencimidazol
RS52260B (en) N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
AR044943A1 (es) Procedimiento para la sintesis de perindopril y sales farmaceuticamente aceptables del mismo

Legal Events

Date Code Title Description
FC Application refused